GlycoMimetics Inc (GLYC)
1.855
+0.02
(+1.09%)
USD |
NASDAQ |
Apr 24, 16:00
1.85
0.00 (0.00%)
Pre-Market: 08:35
GlycoMimetics Enterprise Value: 77.76M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 77.76M |
| April 23, 2024 | 76.47M |
| April 22, 2024 | 74.22M |
| April 19, 2024 | 82.27M |
| April 18, 2024 | 97.42M |
| April 17, 2024 | 105.15M |
| April 16, 2024 | 96.78M |
| April 15, 2024 | 103.54M |
| April 12, 2024 | 112.89M |
| April 11, 2024 | 119.66M |
| April 10, 2024 | 116.11M |
| April 09, 2024 | 130.93M |
| April 08, 2024 | 125.13M |
| April 05, 2024 | 135.45M |
| April 04, 2024 | 132.87M |
| April 03, 2024 | 136.41M |
| April 02, 2024 | 148.98M |
| April 01, 2024 | 154.14M |
| March 28, 2024 | 151.56M |
| March 27, 2024 | 163.16M |
| March 26, 2024 | 141.89M |
| March 25, 2024 | 139.96M |
| March 22, 2024 | 147.05M |
| March 21, 2024 | 143.82M |
| March 20, 2024 | 154.78M |
| Date | Value |
|---|---|
| March 19, 2024 | 147.05M |
| March 18, 2024 | 138.67M |
| March 15, 2024 | 123.20M |
| March 14, 2024 | 126.27M |
| March 13, 2024 | 122.41M |
| March 12, 2024 | 126.92M |
| March 11, 2024 | 123.06M |
| March 08, 2024 | 134.00M |
| March 07, 2024 | 138.51M |
| March 06, 2024 | 144.95M |
| March 05, 2024 | 144.95M |
| March 04, 2024 | 153.96M |
| March 01, 2024 | 152.03M |
| February 29, 2024 | 144.30M |
| February 28, 2024 | 143.02M |
| February 27, 2024 | 152.68M |
| February 26, 2024 | 155.25M |
| February 23, 2024 | 144.95M |
| February 22, 2024 | 146.88M |
| February 21, 2024 | 150.74M |
| February 20, 2024 | 172.64M |
| February 16, 2024 | 165.55M |
| February 15, 2024 | 157.18M |
| February 14, 2024 | 156.54M |
| February 13, 2024 | 157.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-78.44M
Minimum
Mar 18 2020
370.98M
Maximum
May 06 2019
39.05M
Average
25.80M
Median
Jun 30 2020
Enterprise Value Benchmarks
| Altimmune Inc | 304.12M |
| Cellectar Biosciences Inc | 95.21M |
| PDS Biotechnology Corp | 86.32M |
| Syros Pharmaceuticals Inc | 35.82M |
| Precision BioSciences Inc | -26.35M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.079M |
| Revenue (Quarterly) | 0.01M |
| Total Expenses (Quarterly) | 9.600M |
| EPS Diluted (Quarterly) | -0.14 |
| Profit Margin (Quarterly) | -90.79K% |
| Earnings Yield | -31.27% |
| Normalized Earnings Yield | -31.27 |